VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing medicines for anxiety, depression, and other CNS disorders. Their CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray in Phase III development for treating anxiety in adults with social anxiety disorder. Additionally, they are preparing PH10, a neuroactive nasal spray, for Phase 2B clinical development as a stand-alone treatment for major depressive disorder. They also have AV-101, an oral N-methyl-D-aspartate receptor antagonist, in development for various conditions. The company generates revenue through the development and potential commercialization of these CNS therapies.

Products

• PH94B - Rapid-onset neuroactive nasal spray for anxiety disorders

• PH10 - Neuroactive nasal spray for major depressive disorder

• AV-101 - Oral N-methyl-D-aspartate receptor antagonist for multiple conditions